LeMaitre Vascular Inc LMAT

Healthcare Medical Devices

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Company’s principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.

NDAQ:LMAT - Post by User

LeMaitre Vascular Inc

<< Previous

Bullboard Posts

Post by aett258on Oct 27, 2016 8:26am

161 Views

Post# 25391469

Q3 2016 Record Sales $23.2 mm (+22%), Record Op. Inc (+61%)

LeMaitre Q3 2016 Record Sales $23.2 mm (+22%), Record Op. Income $5.3 mm (+61%)

LMAT | 16 hours ago

BURLINGTON, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, today reported Q3 2016 results, provided increased guidance, and announced a $0.045/share dividend.

Q3 2016 Results

Record sales of $23.2mm, +22% vs. Q3 2015

Record operating income of $5.3mm vs. $3.3mm, +61%

Record net income of $3.2mm vs. $2.1mm, +54%

Record earnings of $0.17 per diluted share vs. $0.11, +48%

Record EBITDA of $6.1mm vs $4.0mm, +55%

Cash & equivalents up $5.3mm during the quarter to $34.7mm

Q3 2016 sales of $23.2mm increased 22% (+20% organic) vs. Q3 2015. XenoSure and valvulotomes led growth. International sales and The Americas sales both increased 22%.

Gross margin improved to 73.3% in Q3 2016 from 71.0% in Q3 2015 largely due to XenoSure and other production efficiencies, improved product mix, and average selling price increases.

Operating expenses in Q3 2016 were $11.7mm, a 15% increase vs. the year-earlier quarter. The Company ended the quarter with 91 sales reps vs. 82 at the end of Q3 2015.

George W. LeMaitre, Chairman and CEO said, “Sales increased 22% in Q3, while operating profits were up 61%. We continue to pursue 10% annual sales growth and 20% annual profit growth.”

Read more at https://www.stockhouse.com/news/press-releases/2016/10/26/lemaitre-q3-2016-record-sales-23-2-mm-22-record-op-income-5-3-mm#xHxDEEDFtkLGdp6x.99

<< Previous

Bullboard Posts

How a small-cap tech stock is broadening MRI technology